SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biomatrix (BXM) Looking Great
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John McCarthy who wrote (175)11/12/1997 9:54:00 AM
From: pkwknk  Read Replies (1) of 569
 
...recently completed national meeting of ortho knee surgeons revealed 1) although the absolute science of synvisc is not perfect, it can fill a big void as substitute for unsatisfying steroid injections 2) reimbursement issues of MD profit on drug, as well as medicare reimbursement for both injection and office visit are key incentives that MD's have expressed and hopefully Wyeth is hearing 3) most MD's have not seen a rep in there office yet, so rollout is very early 4) overall in US internists as well as rheumatologists and ortho MD's will jump on bandwagon if proper incentives are alligned because there is just no good alternative the steroid injections or oral NSAI drugs

My take is that if Wyeth is as focused on these isuues as they should be, the 6-12 month earnings visibility here can result in explosive share price move...
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News